MorphoSys signs Sloning technology alliance with Pfizer
Used to create gene and protein libraries
German biotechnology firm MorphoSys has announced an agreement between its recently acquired subsidiary Sloning BioTechnology and Pfizer for the use of Sloning’s Slonomics technology for the creation of gene and protein libraries.
The technology will be installed at Pfizer’s subsidiary Rinat Neuroscience in South San Francisco, California, US.
Under the terms of the agreement, MorphoSys will receive an upfront payment this year for an undisclosed amount, with the potential for annual license fees over the patent lifetime of the Slonomics platform.
Sloning's Slonomics technology uses sets of double stranded DNA triplets to build highly diverse combinatorial gene libraries. MorphoSys acquired the firm in October 2010.
‘This alliance with Pfizer creates immediate value for our shareholders and is just the beginning of what we expect to be a considerable return-on-investment from the combined technology platforms of MorphoSys and Sloning in the years ahead,’ said Simon Moroney, chief executive of MorphoSys.
